CAJ | 학술논문

目的：观察新型靶向治疗药Brentuximab vedotin治疗复发性或难治性霍奇金淋巴瘤（HL）的临床疗效和不良反应。方法选取我院住院治疗的12例复发性或难治性HL患者，经病理及免疫组化证实为CD30抗原阳性的HL。所有病例均接受过二线或三线方案化疗，化疗中位数13个疗程。7例曾接受自体干细胞移植，其中2例行自体干细胞移植后因复发接受异基因干细胞移植。给药方法：Brentuximab vedotin单药剂量1.2～1.8mg/kg，静脉滴注，每21天给药1次。患者共接受2～16个疗程，治疗中位数4个疗程。结果完全缓解2例（17%），部分缓解7例（58%），稳定2例（17%），进展死亡1例（8%）。主要不良反应有乏力、白细胞减少、发热、脱发、转氨酶增高、恶心、末梢神经炎、疼痛等，患者均可耐受。结论 Brentuximab vedotin治疗复发或难治性HL具有良好的临床疗效，不良反应轻微，患者多能耐受。
목적：관찰신형파향치료약Brentuximab vedotin치료복발성혹난치성곽기금림파류（HL）적림상료효화불량반응。방법선취아원주원치료적12례복발성혹난치성HL환자，경병리급면역조화증실위CD30항원양성적HL。소유병례균접수과이선혹삼선방안화료，화료중위수13개료정。7례증접수자체간세포이식，기중2례행자체간세포이식후인복발접수이기인간세포이식。급약방법：Brentuximab vedotin단약제량1.2～1.8mg/kg，정맥적주，매21천급약1차。환자공접수2～16개료정，치료중위수4개료정。결과완전완해2례（17%），부분완해7례（58%），은정2례（17%），진전사망1례（8%）。주요불량반응유핍력、백세포감소、발열、탈발、전안매증고、악심、말소신경염、동통등，환자균가내수。결론 Brentuximab vedotin치료복발혹난치성HL구유량호적림상료효，불량반응경미，환자다능내수。
Objective To determine the efficiency and adverse reaction of the new targeted drug-Brentuximab vedotin, in treatment of patients with relapsed or refractory Hodgkin’s lymphoma(HL). Methods Twelve patients with relapsed or refractory CD30 antigen-positive HL confirmed by pathology and immunohistochemistry treated in our hospital were enrolled in this study. All patients had received the second- or third-line chemotherapy regimens, with median 13 courses of chemotherapy. Seven patients had been treated with autologous stem cell transplantation, among which, 2 cases also underwent allogeneic stem cell transplantation because of relapse after autologous stem cell transplantation. Brentuximab vedotin was given at a dose of 1.2 to 1.8mg/kg, via intravenous injection, for a treatment phase of 21d. Patients received 2 to 16 treatment courses, with a median number of 4 courses. Results Complete remission was achieved in 2 cases(17%), partial remission in 7 cases(58%). Two out of 12 cases(17%) reached a stable condition, and 1 case died(8%). Main adverse reactions included fatigue, leukocyte reduction, fever, hair loss, elevated transaminases, nausea, peripheral neuritis, pain, etc. All of them were tolerated by this cohort of patients. Conclusion Brentuximab vedotin has good clinical efficacy in relapsed or refractory HL and has mild adverse reactions, which is tolerable for the patients.